Rockwell Medical, Inc. — FY2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012. This is an annual filing; selected fourth-quarter results are noted below. Rockwell manufactures and distributes hemodialysis concentrates and related supplies, while investing heavily in renal drug development, principally investigational SFP iron therapy. Concentrates and dialysates accounted for more than 92% of revenue.
Financial performance and liquidity
| Metric | FY2012 | FY2011 |
|---|---|---|
| Revenue | $49.84 million | $48.97 million |
| Gross profit / margin | $6.69 million / 13.4% | $5.64 million / 11.5% |
| Operating loss | $54.26 million | $21.68 million |
| Net loss | $54.02 million | $21.44 million |
| Loss per diluted share | $2.65 | $1.21 |
| Cash used in operating activities | $30.75 million | $10.78 million |
| Cash and investments at year-end | $4.71 million | $17.53 million |
| Current assets / current liabilities | $13.15 million / $26.99 million | $25.90 million / $13.69 million |
- Research and product development expense rose to $48.27 million from $17.81 million, primarily for SFP Phase 3 trials. SG&A increased to $12.68 million from $9.52 million; the company cited higher non-cash equity compensation.
- Year-end working capital was negative $13.84 million. Accounts payable rose to $14.83 million from $5.36 million, and accrued R&D liabilities increased to $9.83 million from $5.91 million.
- Debt was minimal: capital lease obligations were $2,280, with no long-term debt reported. Operating lease commitments totaled $6.08 million.
- FY2012 financing included $18.23 million of proceeds from common shares and warrants; the company reported receiving net proceeds of $16.0 million from a February 2012 equity offering.
Fourth-quarter results
Q4 2012 revenue was $13.00 million versus $11.90 million in Q4 2011; gross profit was $1.70 million versus $1.54 million. Net loss was $13.67 million versus $8.95 million, with R&D expense of $11.75 million versus $7.87 million.
Changes versus prior period
Annual sales increased 1.8%, while gross profit rose 18.6% and gross margin improved by 1.9 percentage points. Management attributed the margin improvement to higher-margin product and customer mix, including CitraPure and dry acid concentrates, and cost controls. Domestic sales increased 3.9% to $44.2 million; international sales declined 12.1% to $5.6 million. The much larger net loss and operating cash outflow reflected sharply higher clinical-development spending. Cash and investments fell by approximately $12.8 million year over year.
Outlook, risks and unusual items
- Funding and going concern: The auditor included a going-concern explanatory paragraph, citing recurring losses, negative working capital and insufficient liquidity. Management said it was negotiating additional equity and debt financing and pursuing partnerships. It warned that unavailable or inadequate funding could force delays, reductions or cessation of development or operations.
- Pipeline and plans: The two pivotal SFP CRUISE trials were expected to report in the second half of 2013. The company planned to submit an SFP NDA within the following 12 months if trials succeeded. Calcitriol, an FDA-approved generic whose manufacturing-site change still required regulatory approval, was expected to launch in the second half of 2013.
- Clinical update: Top-line PRIME results announced in February 2013 showed a statistically significant 37.1% reduction in ESA use versus control; 103 patients received study drug. These results do not establish FDA approval or commercial success.
- Customer concentration: DaVita accounted for 49% of FY2012 sales, up from 48% in 2011. The supply agreement with this largest domestic chain ran through the end of 2013; management expected renewal, but the filing gives no assurance.
- Other risks: SFP trial, approval, reimbursement and adoption risks; competition and pricing pressure; dependence on government-funded dialysis reimbursement; volatility in chemical and fuel costs; and potential dilution from future financing and outstanding options and warrants. The company reported 2.23 million warrants and 5.99 million options outstanding at year-end.
- The company reported ordinary-course legal proceedings and said their resolution was not expected to have a material effect. The auditor gave an unqualified opinion on the financial statements and internal controls; management and the auditor concluded internal control over financial reporting was effective at year-end.
Key facts for investors to verify
- Current cash runway, financing terms and whether capital raised is sufficient to fund operations and complete SFP development.
- Final CRUISE trial outcomes, timing and regulatory filing requirements; distinguish the PRIME findings from pivotal-trial evidence.
- FDA approval status and launch economics for Calcitriol, including manufacturing-site approval and competitive conditions.
- Renewal and terms of the DaVita supply agreement, given the customer’s 49% revenue concentration.
- Cash conversion and working-capital trends, particularly the growth in accounts payable and accrued R&D liabilities.
- Potential dilution from equity financing, options and warrants; the filing reports 21.49 million common shares outstanding at year-end.